Global beauty giant L’Oréal signed a contract on June 29 with domestic biotech firm OliX to discover “short interfering ribonucleic acid (siRNA)” substances for nail and toenail health. This substance ...

To specifically target the mold Aspergillus fumigatus, the researchers combined an RNAi approach with optimized delivery technology from nanomedicine. Ribonucleic acid (RNA) plays a central role in ...

The U.S. RNAi Technology Market is projected to grow from USD 1.24 Billion in 2025 to USD 4.77 Billion by 2035, while the ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

-- Novel approach to gene knockdown uses proprietary CASi (Conditionally Activated siRNA) molecules optimized to “switch” on, activating siRNA therapeutics only in selected cells -- -- CASi platform, ...

Olix announced on June 29 that it has signed a new pipeline collaboration framework agreement with L'Oréal Group. Under this agreement, the two compan ...

LONDON--(BUSINESS WIRE)--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference ...

Researchers at Mirus Bio Corporation have developed a technique to target specific cells with a genetic "silencing switch," known as RNA interference (RNAi), which blocks the production of ...